As Direct-to-Consumer Pharmacy Grows, Who Is Safeguarding Patient Safety?

Key Takeaway: Direct-to-consumer pharmacy models can improve access and affordability, but they can also fragment a member’s medication history. When cash-pay prescriptions sit outside the pharmacy benefit, plans need a way to preserve clinical oversight for interactions, duplicate therapies and dosing risks.

Over the past few years, a new pharmacy model has captured public attention.

Direct-to-consumer (DTC) drug platforms, including online pharmacies, subscription services, telehealth-linked dispensaries, and cash-pay generic programs, promise patients something simple: lower prices, up-front pricing, and medications delivered directly to a patient’s door.

Some DTC models offer meaningful savings on common generics. Others simplify the purchasing process, improve access, and bypass layers of intermediaries. For patients frustrated with complexity, the appeal is obvious.

And to be clear: any initiative that increases affordability and transparency in healthcare deserves recognition.

But innovation, like medication itself, can have side effects.

How Direct-to-Consumer Pharmacy Models Change Medication Oversight

As patients mix cash-pay DTC purchases with prescriptions filled through their insurance benefit, a new clinical blind spot is emerging.

A patient may order a GLP-1 through a telehealth platform, purchase generics from a cash-pay pharmacy, and still rely on their insurance benefit for other prescriptions, unintentionally creating a disconnected medication history.

For drugs like GLP-1s, cardiovascular medications, anticoagulants, antidepressants, or other chronic disease therapies, this blind spot can quickly turn into harm.

The model itself removes critical layers of oversight that traditionally exist within integrated pharmacy benefit systems, layers designed to detect duplication, dangerous drug-to-drug interactions, dosing errors, and clinical misalignment in real time.

The question is not whether DTC lowers prices. The question is: who is safeguarding patient safety?

Medication safety is already one of the most vulnerable areas in healthcare.

Why Medication Safety Remains a Systemic Challenge

Even within traditional pharmacy systems, where utilization review, prior authorization, and integrated claims visibility are standard, medication errors are serious problem:

• More than 100,000 medication errors are reported to the FDA each year
• 7,000–9,000 deaths annually are linked to medication mistakes
• 1.3 million patients are harmed each year

Drug utilization review systems are built to flag duplications, dangerous interactions, dosing errors, and contraindications in real time. Clinical teams intervene. Pharmacists are alerted. Prescribers are contacted.

And even with those safeguards in place, errors still happen.

Medication errors are estimated to cost the U.S. healthcare system more than $40 billion annually, with billions tied to preventable mistakes.

Drug-related problems are one of the hidden drivers of hospitalizations, emergency visits, and unnecessary total healthcare spend.

Now consider what happens when parts of a patient’s medication history sit outside of that system, when claims are never adjudicated and no single entity has full visibility.

What Happens When Prescriptions Sit Outside an Integrated Pharmacy Benefit

Traditional pharmacy benefit systems do more than process prescriptions. They connect the dots.

When a prescription runs through an integrated pharmacy benefit system, it is evaluated in the context of the patient’s broader medication history. Potential interactions can be identified. Duplicate therapies can be detected. Dose levels can be assessed before the medication is dispensed.

In a cash-pay direct-to-consumer model, that full visibility isn’t there.

A prescription may be filled appropriately. A pharmacist may review it. But if that medication sits outside the patient’s regular benefit or pharmacy network, it may not be considered alongside everything else the patient is taking.

The issue isn’t whether a prescription is reviewed. It’s whether it’s reviewed in context.

Who Is Most at Risk in a Direct-to-Consumer Pharmacy Model?

The risk created by DTC fragmentation won’t be evenly distributed.

Individuals living with diabetes, cardiovascular disease, autoimmune disorders, depression, or cancer often take multiple medications at the same time. Their safety depends not only on whether each prescription is appropriate on its own, but whether it works safely alongside everything else they are taking.

Polypharmacy is no longer rare. Roughly four in ten adults over the age of 65 take five or more prescription medications.

As that number of therapies increases, the margin for error narrows.

When medication is managed across separate platforms and payment channels, maintaining that coordination becomes more difficult. And as complexity increases, so does risk.

Building Safety into the Future of Direct-to-Consumer Pharmacy

Lower drug costs matter. Transparency matters. Patients deserve both. Direct-to-consumer models have introduced meaningful disruption to a system that has long needed it.

But affordability and safety cannot move in opposite directions. Medication visibility cannot depend solely on where a prescription is purchased or how it is paid for. Patients should not lose clinical oversight simply because they are trying to save money.

Drug-related problems do not care who dispensed the medication. They care whether someone was watching.

The question is not whether direct-to-consumer drug models should exist. They bring needed transparency and challenge long-standing inefficiencies in our system. The question is whether we are building the safeguards to match that innovation.

Because affordability means nothing if the therapy does not end up being safe or effective.

It is time for our industry, PBMs, clinicians, pharmacies, DTC platforms, technology companies, and regulators, to come together and build solutions that ensure no patient loses access to clinical oversight simply because they’re trying to save money.

Innovation and safety must evolve together.

Patient safety must remain the constant.

FAQs For Page

Does direct-to-consumer pharmacy eliminate pharmacist review?

When a medication sits outside a patient's regular benefit or pharmacy network, it may not be evaluated alongside everything else the patient is taking, which is where interactions and duplications can go undetected.

Who is most at risk when medications are managed across separate platforms?

People managing multiple chronic conditions, such as diabetes, cardiovascular disease, or depression, who take several medications at once. Roughly four in ten adults over 65 take five or more prescription medications, and as therapy count rises, the margin for error narrows.

What is a clinical blind spot in pharmacy?

A clinical blind spot occurs when parts of a patient's medication history sit outside any single system of record, so no entity has full visibility. Cash-pay DTC purchases combined with insurance-billed prescriptions can create a disconnected medication history that standard safety checks never see.

What can plan sponsors do about DTC fragmentation?

Plan sponsors can help close the gap by working with a pharmacy benefit partner designed to maintain a complete medication record and apply clinical review in context, so members keep clinical oversight regardless of where a prescription is purchased or how it is paid for.